L1:

L2: iron:
	main: iron is important
	- iron cycle:
		- apical Fe3 reductase -> Fe2
		- Fe2 absorbed by DMT-1 (divalence metal transporter)
		- cellular Fe2 binds ferritin
		- FPN (ferroportin) exports Fe2
		- transferrin carries Fe2
		- TFR1/2 (transferrin receptor) binding endocytoses transferrin
			- Fe2 stored in liver hepatocytes + splenic macrophages
		- hepicidin inhibits FPN
			- induced by IL-6, HFE, TRF2, hemojuvulin
			- downregulated by erythroferrone (when in stress erythropoiesis)

	- iron deficient anemia:
		- signs:
			- hypochromic, microcytic, aniso + poikylocytosis
			- low ferritin
			- low Hg
			- increased TIBC
		- symptoms:
			- lethary, irritability, pallor
			- pica (geo + pagophagia)
			- blue sclera
			- spoon nails
			- hx of heavy menses, guaic +, epistaxis
		- tx: iron supplement


	- thalassemia trait:
		- microcytosis, target cells
		- non-responsive to iron
		- normalish Hg and RDW
		- normal iron

	- anemia of chronic disease
		- normocytic
		- IL-6 -> high hepicidin -> poor iron absorbtion / release from stores
		- signs:
			- low serum iron
			- low TIBC
			- high ferritin

	- hemochromatosis:
		- signs:
			- granular, dark red/brown liver
			- iron in bone marrow
			- high serum Fe
			- high ferritin
			- high iron sat
		- symptoms:
			- vertigo
			- arthritis
			- bronze skins
			- hepatomegaly
			- hair loss
			- memory loss

		- causes:
			- transfusions
			- failed hepicidin signaling


L3: hemolytic anemias:
	main:
	- hemolysis:
		- high LDH
		- urine hemodsiderin
		- high bilirubin
		- high reticulocytes
		- low haptoglobin
	- coombs positive: antibody mediated hemolytic anemia
		- warm / IgG:
			- extravascular hemolysis (in spleen)
			- sometimes fix complement
			- microspherocytes
			- causes: hep c, autoimmune, lymphomas
			- tx: 
				- steroids (first line)
				- rituximab
				- splenectomy
				- treat underlying (TU)

		- cold / IgM:
			- fix complement
			- intravascular + extravascular hemolysis
			- agglutination
			- causes: mycoplasma, mono (EBV/CMV), lymphomas
			- tx:
				- rituximab
				- TU
				- plasma exchange (rare)

	- inherited:
		- G6P deficiency
			- bite + blister cells
			- heinz bodies
			- X-linked, mediterranean/african, oxidative stress (fava beans, anti-malarials, ketoacidosis)
			- tx: transfusions, avoid triggers
		- hereditary spherocytosis / elliptocytosis: splenectomy
	
	- mechanical destruction:
		- thrombotic thrombocytopenia purpura (TTP):
			- ADAMTS13 deficiency -> ultra large vWF -> large clots -> schistocytes
			- microangiopathic hemolysis - thrombotic microangiopathy
			- signs:
				- always: anemia, thrombocytopenia 
				- less common: fever, renal failure, neuro dysfunction
			- tx
				- steroids
				- plasma exchange
				- rituximab
				- caplacizumab (stops vWF - platelet interactions)

	- aquired RBC defect:
		- paroxysmal nocturnal hemoglobinuria (PNH):
			- urine dark in AM -> lighter through day
			- GPI anchor loss (prevents alternate pathway complement)
			- dx: flow cytometry for GPI proteins
			- tx:
				- eculizumab: C5 inhibitor
				- pegcetacoplan: C3 inhibitor
				- transfusions
				- anticoagulation

L4: normal hemostasis
	main:
	- pathways
		- intrinsic: TENET (12, 11, 9, 8, 10)
		- extrinsic: TF -> 7a -> 7a + TF
		- common: 10 -> 2a (thrombin) -> fribin (1) -> 13 -> cross linked
		- fibrinolysis: plasminogen --(tPA | 12a | kallikrein)--> plasmin -> fibrin products
	- specials:
		- thrombin effects:
			- activates 11a and 7a (2nd step each pathway)
			- activates 5 + 8 (the randos)
			- activates 13 (the finisher)
			- binds thrombomodulin -> protein C
		- protein C:
			- inactivates 5 + 8
			- activity promoted by protein S
		- antithrombin:
			- activated by heparin
			- inactivates X, thrombin, 11, 9
		- tissue factor pathway inhibitor (TFPI):
			- complexes 7/TF/Xa, inactivates Xa
		- von willebrand factor:
			- binds exposed collagen
			- cleaved by ADAMTS13
			- protects 8
		- D-dimer:
			- fibrinolysis byproduct
			- high d-dimer -> excessive coagulation, inflammation, or renal failure

	- vitamin K: 2, 7, 9, 10, prothrombin, protein C + S
	- hepatic non vitamin k: 1 (fibrinogen) + 11, antithrombin
	- hemophilias:
		- A: factor 8
		- B: factor 9
		- C (recessive, mild, women): 11


	- PTT: partial thromboplastin time:
		- intrinsic time
		- 23-35s
	- PT: prothrombin time
		- extrinsic time
		- 10-13s


L5: megaloblastic anemia
	main: big blood rbcs -> check folate + cobalamine
	- macrocytic anemias (non-megaloblastic):
		- liver disease
		- alcohol toxicity
		- reticulocytosis: reticulocytes 10% bigger than rbcs
		- hypothyroidism
		- medication induced: chemo / antibiotics
		- myelodysplastic syndromes

	- megaloblastic anemia
		- pathophysiology:
			- normal hg/cell production
			- defect in nuclear replication + division
		- signs:
			- oval macrocyte - MCV > 100 fl
			- hypersegmented neutrophils - 5, 6+ segments
			- pancytopenia
			- reticulocytopenia
			- LDH elevated
			- serum Fe normal or elevated
			- low B12 or folate

		- folate deficient:
			- folate/THF needed for purine synthesis -> cell division
			- folate absorbed by duodenum/jejunum
			- signs:
				- megaloblastic anemia
				- glossitis/stomatitis
				- GI malabsorption (rare)

		- B12 / cobalamin deficient:
			- B12 needed to make folate into THF
			- B12 absorbed in ileum bound to intrinsic factor IF from parietal cells

			- pernicious anemia:
				- autoimmune targetting of parietal cells or IF
				- symptoms: achlorhydria, B12 deficiency / megaloblastic anemia
			- signs:
				- same as folate deficient
				- dementia
				- psych disturbances
				- demyelinating disease
	
		- tx:
			- check homocysteine, methylmalonic acid, if high -> B12 deficiency
			- give B12 + folate
			- transfusions if angina or hemodynamic unstable


L6: prothrombotic disorders
	main:
   - anticoagulant protein deficiency
		- heterozygous:
			- increased VTE, sometimes ATE
			- young age thrombosis
			- increased thrombin production
			- positive FHx

		- homozygous:
			- neonatal purpura fulminans
			- fibrinogenolysis
			- chronic DIC
			- increased thrombin production
			- negative FHx

	- activated protein C resistance
		- factor V leiden (98%)
		- prolonged aPTT
		- 4x VTE risk in het form, higher w/ homo
		- northern european

	- hypercoagulable states
		- prothrombin G20210 > A
			- increased prothrombin production
			- northern european
			- risks in pregnancy + VTE

		- chronic inflammatory disease
			- acute phase reactant / C4b binding protein
				- binds protein S -> inactivates protein S
			- inflammation
				- IL-1 + TNF -> downregulate thrombomodulin -> thrombin becomes coagulant

		- nephrotic syndrome / protein-losing enteropathy
			- loss of protein S + C, antithrombin III
			- remaining S is bound to C4b binding protein

		- antiphospholipid antibody syndrome
			- 30% w/ lupus
			- VTE + ATE
			- false positive RPR
			- recurrent spontaneous abortions

		- lupus anticoagulant
			- do not understand
			- antiphospholipid antibodies

		- thrombotic thrombocytopenia purpura (TTP):
			- sporadic + relapsing
			- fatal w/o treatment, 90% survival w/ treatment
			- MAHA
			- tx:
				- plasmapheresis: replaces ADAMTS13 + removes antibodies
					- aggressive: 1.5-2 exchanges daily
				- steroids: decrease antibody formation
				- ritxuimab
				- vincristine
				- caplicizumab:
					- monoclonal against vWF
					- shortens plasmapheresis treatment duration
					- increases bleeding, relapse more common

		- heparin-induced thrombocytopenia (HIT):
			- allergic reaction to heparin + PF4 complex
			- thrombocytopenia
			- UFH > LWMH, high dose > low, etc

		- disseminated instravascular coagulation (DIC):
			- caused by big bad things
			- microthrombi in microvasculature -> use all clotting factors + platelets + fribinolysis
			- all times elevated, all factors depleted
			- tx:
				- if thrombosis: anticoagulant (heparin)
				- if bleeding: replacements: cryoprecipitate, fresh frozen plasma, platelets
				- TU

L7: thalassemias and hemoglobinopathies
	main:
	- hemoglobin:
		- Ch16: 4 α alleles, 2 ζ alleles
		- Ch11: 2 β alleles, 4 γ alleles, 2 ε 
		- embryonic: 2 ζ + 2 ε
		- fetal: 2 α + 2 γ
		- infant: 2 α + 2 β

 	- thalassemia:
		- underproduction of one of the chains
		- β:
			- excess of α tetramer is toxic
			- microcytic, target cells
			- types:
				- trait (minor):
					- 1 allele
					- anemia
				- major:
					- 2 alleles
					- bony changes (on edge)
					- splenomegaly
					- major cause of death: cardiomyopathy
					- tx:
						- regular transfusions
						- iron chelation to stop hemochromatosis
						- stem cell transplant
		- α:
			- γ4 tetramer is HgB Barts
			- β4 tetramer is Hgb H
			- unstable tetramers -> cause hemolytic anemia
			- α thalassemia trait:
				- 2 alleles
				- HgB Barts detectable as newborn
			- α thalassemia major / Hg H disease:
				- HgB Barts detectable as newborn
				- HgH after 6 mos

	- hemoglobinopathy:
		- defect in hemoglobin protein chain
		- sickle cell:
			- sickle cell anemia: SS alleles
				- dactylitis
				- spenic infarcts
				- howel jolly bodys
				- tx:
					- penicillin
					- pain management
					- yearly transcranial doppler
						- transfusions for high stroke risk
					- hydroxyurea -> increases γ chain production
					- bone marrow transplant

			- sickle Hgb C disease: SC alleles
			- sickle β+ thalassemia: Sβ+ alleles
			- sickle β0 thalassemia: Sβ0 alleles
			- look at chart for HgB, retic, MCV values
			- S allele:
				- GAG -> GTG codon 6 on β globin

L8: bleeding disorders
	main:
	- hemophilia:
		- symptoms:
			- hemarthrosis
			- hematuria
			- hemorrhage
			- GI bleeds
			- epistaxis
			- hematoma
		- factor replacement:
			- eventual antibody formation against factors -> refractory
		- tx:
			- prophylactic:
				- 8: 3x week
				- 9: 2x week
			- on demand factor replacement
			- emicizumab:
				- binds 9 + 10 -> activates 10 w/o 8
				- subq, biweekly or less
	
	- von willebrands disease:
		- autosomal dominant
		- more common in women
		- most common in type O
		- potentially normal aPTT
		- symptoms:
			- menorrhagia
			- easy bruising
			- dental/surgical bleeding
		- tx:
			- aminocaprioic acid / tranexamic acid:
				- oral fibrinolysis inhibitors
			- desmopressin (ddAVP):
				- induce vWF surge
			- vWF concentrates
			- cryoprecipitate

	- hemophilia C / factor XI deficiency:
		- autosomal recessive, ashkenazi
		- aPTT often prolonged
		- tx: fresh frozen plasma if needed

	- vitamin K deficiency:
		- prolonged PT/INR

	- immune thrombocytopenic purpura (ITP):
		- antibodies to platelets
		- dx: exclusion
		- symptoms:
			- petechiae
			- purpura
		- signs:
			- no platelets on smear
		- tx:
			- steroids
			- IV Ig
			- IV anti-D (WinRho)
			- splenectomy (rare)
			- rituximab
			- thrombopoietin mimetics
				- romiplostim
				- eltrombopag

	- uremic platelet dysfunction:
		- endothelial dysfunction
		- platelet dysfunction
		- tx:
			- dialysis, partially treats
			- acute: desmopressin ddAVP

	- disseminated intravascular coagulation (DIC):
		- causes:
			- infections: meningococcemia + septicemia
			- hypertransfusion w/ rbcs
			- adenocarcinomas
			- acute leukemias
			- venoms
		- symptoms:
			- oozing from access sites
			- purpura
			- gangrene
		- tx:
			- cryoprecipitate
			- heparin

L9: hematologic therapies:
	main:
	- antithrombotics:
		- anticoagulants:
			- heparin:
				- sulfated polysaccharides from porcine intestine mucosa or bovine lung
				- unfractionated heparin:
					- variable bioavailability (UH)
					- reversible with protamine (+ charges blocks - heparin)
					- monitoring required to ensure therapeutic dose
					- higer risk for thrombocytopenia

				- low molecular weight heparins (LWMH)
					- smaller polysaccharides
					- no monitoring, except high risk
					- longer half life, 1-2x per day
					- partially reversible
					- renally excreted
					- black box w/ regional anesthesia
					- types:
						- enoxaparin: VTE prophylaxis + tx, ACS
						- dalteparin: same as enoxaparin + VTE tx w/ cancer

				- fondaparinux:
					- semisynthetic sulfated pentasaccharide
					- inhibits only factor Xa
					- subq, daily dosing
					- no thrombocytopenia
					- superior to LMWH
					- risk of wound hematomas in orthopedics
			
			- warfarin:
				- vitamin K reductase inhibitor
				- metabolized by CYP2C9
				- monitor w/ PT/INR
				- lots of interactions + zero order kinetics
				- reversible: vitamin K
				- dosing:
					- overlap with parenteral agent for 5 days
					- high variability

			- Xa inhibitors:
				- wider therapeutic range
				- few interactions (no food)
				- no monitoring
				- VTE prophylaxis + tx, CAD, stroke prevention w/ non-valvular afib

				- rivaroxaban:
					- non inferior to warfarin
					- 1-2x daily
				- apixaban:
					- superior to warfarin
					- 2x daily
				- edoxaban:
					- 1x daily
					- VTE, VTE tx w/ cancer
				- betrixaban:
					- 1x daily
					- VTE

			- direct thrombin inhibitors:
				- block active site of thrombin
				- more potent than heparins
				- irreversible

				- argatroban:
					- HIT, TEs, ACS
					- half life 30-40 mins
					- problems w/ liver
				- bivalirudin:
					- hirudin derivative
					- unstable angina/angioplasty
					- short acting
				- dabigatran:
					- oral
					- superior to warfarin for TE w/ afib
					- VTE prophylaxis + tx
					- 2x daily
					- problematic with renal failure

	- growth factors:
		- thrombopoetin (TPO):
			- used for ITP or liver disease
			- types:
				- romiplostim
				- eltrombopag
				- avvatrombopag
				- lusotrombopag
		
		- GM-CSF - sargramostim:
			- granulocyte-monocyte colony stimulating factor

		- G-CSF:
			- neutrophil stimulator
			- use: post-chemotherapy
			- types:
				- filgrastim
				- pegilgrastim

		- EPO stimulators:
			- erythropoietin
			- darbepoetin
			- methoxy-polyethylene glycol-epoetin beta



L10:
